In response to the lack of driver oncoprotein BCR-ABL1, TKI-resistant CML cells underwent apoptosis regardless of the presence of the clinically relevant T315I mutation by day 5 after redosing with ASP210. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.